drugset / Trial / NCT00770510

A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)

NCT00770510

Phase 2/3 Completed 192 enrolled Eisai Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to investigate and evaluate the efficacy of Eszopiclone in Japanese participants with primary insomnia.

Timeline

Start
2008-09
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 1 mg Oral
Subject Eszopiclone Small molecule 2 mg Oral
Subject Eszopiclone Small molecule 3 mg Oral
Comparator Zolpidem Small molecule 10 mg Oral

Indications